Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Gastric Cancer Management and Outcomes, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, and Gastrointestinal Tumor Research and Treatment.
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design.
A cDC1-NK/T-Malignant Cell Circuit Drives Immunogenic Remodeling Under PD-1 Blockade in Gastric Cancer.
Neutrophil-Macrophage Interactions Shape Inflammatory Macrophage Remodeling in Gastric Cancer During Chemo-Immunotherapy.
Lenvatinib combined with PD-1 blockade therapy benefits gastric cancers through immunosuppressive macrophage modulation.
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment.
The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer.
Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational Study.
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Supplementary Figure S2 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
Figure S4 from The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Figure S2 from The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Figure 3 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Supplementary Figure S4 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
Table S4 from The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Figure 2 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Figure S1 from The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Supplementary Table S1 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
Supplementary Figure S5 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
Figure S6 from The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Figure 4 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Supplementary Figures and Tables from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Figure S5 from The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Table S3 from The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Supplementary Table S3 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
Supplementary Figure S3 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
Figure S3 from The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Supplementary Table S2 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort
Supplementary Table S4 from Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort